Lombard AP - Search Results

1

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.

Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. Liu C, et al. Among authors: lombard ap. Oncogene. 2021 Sep;40(35):5379-5392. doi: 10.1038/s41388-021-01914-2. Epub 2021 Jul 16. Oncogene. 2021. PMID: 34272475 Free PMC article.

2

The emerging role of the androgen receptor in bladder cancer.

Lombard AP, Mudryj M. Lombard AP, et al. Endocr Relat Cancer. 2015 Oct;22(5):R265-77. doi: 10.1530/ERC-15-0209. Epub 2015 Jul 30. Endocr Relat Cancer. 2015. PMID: 26229034 Review.

3

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Liu C, et al. Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28. Mol Cancer Ther. 2017. PMID: 27794047 Free PMC article.

4

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. Armstrong CM, et al. Among authors: lombard ap. Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358. Prostate. 2017. PMID: 28485104 Free PMC article.

5

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Liu C, et al. Among authors: lombard ap. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12. Mol Cancer Ther. 2017. PMID: 28500234 Free PMC article.

6

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. Lombard AP, et al. Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11. Mol Cancer Ther. 2017. PMID: 28698198 Free PMC article.

7

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Lombard AP, et al. Mol Cancer Ther. 2018 Oct;17(10):2197-2205. doi: 10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11. Mol Cancer Ther. 2018. PMID: 29891490 Free PMC article.

8

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Liu C, et al. Among authors: lombard ap. Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x. Nat Commun. 2018. PMID: 30446660 Free PMC article.

9

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Lombard AP, et al. Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 7. Transl Oncol. 2019. PMID: 31075528 Free PMC article.

10

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.

Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. Liu C, et al. Among authors: lombard ap. Mol Cancer Ther. 2019 Oct;18(10):1875-1886. doi: 10.1158/1535-7163.MCT-18-1322. Epub 2019 Jul 15. Mol Cancer Ther. 2019. PMID: 31308078 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters